Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Osi-930. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR known ✓ | P35968 | 10/20 | 1.00 |
| ▸ | KIT known ✓ | P10721 | 1/20 | 1.00 |
| ▸ | FLT1 known ✓ | P17948 | 7/20 | 0.48 |
| ▸ | RAF1 | P04049 | 1/20 | 1.00 |
| ▸ | LCK | P06239 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 1/20 | 1.00 |
| ▸ | MAP3K20 | Q9NYL2 | 1/20 | 1.00 |
| ▸ | RIPK3 | Q9Y572 | 1/20 | 1.00 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.45 |
| ▸ | TCF7L2 | Q9NQB0 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.44 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.44 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.44 |
| ▸ | IGF1R | P08069 | 2/20 | 0.43 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Osi-930 SCHEMBL29352171 | 1.00 | KDR (1.00) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL14066606 | 0.90 | KDR (0.81) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL3364485 | 0.90 | KDR (0.81) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL3361575 | 0.90 | KDR (0.81) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL14076809 | 0.89 | KDR (0.80) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL3362720 | 0.89 | KDR (0.79) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL3359832 | 0.89 | KDR (0.79) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL3363327 | 0.88 | KDR (0.79) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL3361185 | 0.88 | KDR (0.79) | KDRRAF1LCKRETCYP3A4 | |
| SCHEMBL20805543 | 0.88 | KDR (0.78) | KDRRAF1LCKRETCYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 110 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2021144360-A1 | SMALL MOLECULE CSF-1R INHIBITORS IN THERAPEUTIC AND COSMETIC USES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-22 | — | — | WO | claimed |
| EP-3650040-A1 | VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ATOPIC DERMATITIS | Galderma Research & Development (FR) | 2020-05-13 | — | — | EP | claimed |
| WO-2018224614-A1 | VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ACNE | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2018-12-13 | — | — | WO | claimed |
| EP-3412288-A1 | VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ACNE | Galderma Research & Development (FR) | 2018-12-12 | — | — | EP | claimed |
| EP-1590328-B1 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2012-02-22 | — | — | EP | claimed |
| EP-2364699-A1 | Joint use of sulfonamide based compound with angiogenesis inhibitor | Eisai R&D Management Co., Ltd. (JP) | 2011-09-14 | — | — | EP | claimed |
| CN-101998865-A | Combined treatment with an EGFR kinase inhibitor and an inhibitor of C-KIT | OSI PHARM INC | 2011-03-30 | — | — | CN | claimed |
| EP-2227254-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI Pharmaceuticals, Inc. (US) | 2010-09-15 | — | — | EP | claimed |
| WO-2010088000-A2 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2010-08-05 | — | — | WO | claimed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | claimed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | claimed |
| WO-2009073139-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | claimed |
| US-20090136517-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. | 2009-05-28 | — | — | US | claimed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | claimed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | claimed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | claimed |
| US-6949563-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2005-09-27 | — | — | US | claimed |
| US-20040186124-A1 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | claimed |
| WO-2026087699-A1 | NEW TREATMENT OF NON-SMALL CELL LUNG CANCER | PIERRE FABRE MEDICAMENT (FR) | 2026-04-30 | — | — | WO | disclosed |
| EP-4416306-A1 | METHODS FOR DETERMINING THE LIKELIHOOD OF A MALIGNANT DISEASE RESPONDING TO TREATMENT WITH A PHARMACEUTICAL INHIBITOR | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2024-08-21 | — | — | EP | disclosed |
| US-20230212679-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| US-20230212679-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2023-07-06 | — | — | US | disclosed |
| WO-2023062115-A1 | METHODS FOR DETERMINING THE LIKELIHOOD OF A MALIGNANT DISEASE RESPONDING TO TREATMENT WITH A PHARMACEUTICAL INHIBITOR | Rheinische Friedrich-Wilhelms-Universität Bonn (DE) | 2023-04-20 | — | — | WO | disclosed |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-12-01 | — | — | US | disclosed |
| US-20220305003-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2022-09-29 | — | — | US | disclosed |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. (US) | 2022-06-02 | — | — | US | disclosed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | disclosed |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2022-05-17 | — | — | US | disclosed |
| EP-3982977-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | Children's Medical Research Institute (AU) | 2022-04-20 | — | — | EP | disclosed |
| US-11230589-B2 | Fusion molecules and uses thereof | FOUNDATION MEDICINE, INC. (US) | 2022-01-25 | — | — | US | disclosed |
| WO-2021144360-A1 | SMALL MOLECULE CSF-1R INHIBITORS IN THERAPEUTIC AND COSMETIC USES | F. HOFFMANN-LA ROCHE AG (CH) | 2021-07-22 | — | — | WO | disclosed |
| WO-2020248018-A1 | METHODS OF TREATING CANCER WITH AN INHIBITOR OF ZNF827 | CHILDREN'S MEDICAL RESEARCH INSTITUTE (AU) | 2020-12-17 | — | — | WO | disclosed |
| US-20200237670-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2020-07-30 | — | — | US | disclosed |
| US-20200199689-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-06-25 | — | — | US | disclosed |
| US-20200199689-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2020-06-25 | — | — | US | disclosed |
| EP-3650040-A1 | VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ATOPIC DERMATITIS | Galderma Research & Development (FR) | 2020-05-13 | — | — | EP | disclosed |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2020-03-19 | — | — | US | disclosed |
| WO-2020056162-A1 | DETECTING AND/OR SUBTYPING CIRCULATING HYBRID CELLS THAT CORRELATE WITH STAGE AND SURVIVAL | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2020-03-19 | — | — | WO | disclosed |
| WO-2019201123-A1 | MULTIFUNCTIONAL COMPOUND, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF IN PHARMACEUTICALS | 四川科伦博泰生物医药股份有限公司 | 2019-10-24 | — | — | WO | disclosed |
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2019-03-21 | — | — | US | disclosed |
| EP-3412288-A1 | VEGF INHIBITORS FOR USE FOR PREVENTING AND/OR TREATING ACNE | Galderma Research & Development (FR) | 2018-12-12 | — | — | EP | disclosed |
| WO-2018217766-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | WHITEHEAD INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2018-11-29 | — | — | WO | disclosed |
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-25 | — | — | US | disclosed |
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2018-01-25 | — | — | US | disclosed |
| WO-2017176792-A1 | METHODS OF PREVENTING OR REDUCING A FIBROTIC RESPONSE USING CSF 1R INHIBITORS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 2017-10-12 | — | — | WO | disclosed |
| US-20170191137-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170191137-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20170191137-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2017-07-06 | — | — | US | disclosed |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | FOUNDATION MEDICINE, INC. | 2016-01-14 | — | — | US | disclosed |
| US-20150374767-A1 | Treatment of Cancer | VIRTTU BIOLOGICS LIMITED (GB) | 2015-12-31 | — | — | US | disclosed |
| US-9006240-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006240-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-9006240-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-14 | — | — | US | disclosed |
| US-8969344-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969344-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| US-8969344-B2 | Method for assay on the effect of vascularization inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-03-03 | — | — | US | disclosed |
| WO-2014128487-A1 | TREATMENT OF CANCER | VIRTTU BIOLOGICS LIMITED (GB) | 2014-08-28 | — | — | WO | disclosed |
| US-8772269-B2 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8772269-B2 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-8772269-B2 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-07-08 | — | — | US | disclosed |
| US-20140148483-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-29 | — | — | US | disclosed |
| US-20140148483-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-29 | — | — | US | disclosed |
| US-20140148483-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-05-29 | — | — | US | disclosed |
| EP-2711433-A1 | METHOD FOR PREDICTING EFFECTIVENESS OF ANGIOGENESIS INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2014-03-26 | — | — | EP | disclosed |
| US-20130085152-A1 | Method For Assay On The Effect Of Vascularization Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085152-A1 | Method For Assay On The Effect Of Vascularization Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| US-20130085152-A1 | Method For Assay On The Effect Of Vascularization Inhibitor | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2013-04-04 | — | — | US | disclosed |
| WO-2012157672-A1 | METHOD FOR PREDICTING EFFECTIVENESS OF ANGIOGENESIS INHIBITOR | エーザイ・アール・アンド・ディー・マネジメント株式会社 (JP) | 2012-11-22 | — | — | WO | disclosed |
| EP-1590328-B1 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-1590328-B1 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2012-02-22 | — | — | EP | disclosed |
| EP-2364699-A1 | Joint use of sulfonamide based compound with angiogenesis inhibitor | Eisai R&D Management Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| CN-101998865-A | Combined treatment with an EGFR kinase inhibitor and an inhibitor of C-KIT | OSI PHARM INC | 2011-03-30 | — | — | CN | disclosed |
| EP-2281901-A2 | Anti-tumour pharmaceutical composition with angiogenesis inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| EP-2281901-A2 | Anti-tumour pharmaceutical composition with angiogenesis inhibitors | Eisai R&D Management Co., Ltd. (JP) | 2011-02-09 | — | — | EP | disclosed |
| EP-2227254-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI Pharmaceuticals, Inc. (US) | 2010-09-15 | — | — | EP | disclosed |
| WO-2010088000-A2 | ANTIFIBROTIC COMPOUNDS AND USES THEREOF | ANGION BIOMEDICA CORP. (US) | 2010-08-05 | — | — | WO | disclosed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100105031-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | ESAI R & D MANAGEMENT CO., LTD. (JP) | 2010-04-29 | — | — | US | disclosed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2010-04-15 | — | — | US | disclosed |
| US-7696225-B2 | (2-carboxamido)(3-Amino) thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696225-B2 | (2-carboxamido)(3-Amino) thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| US-7696225-B2 | (2-carboxamido)(3-Amino) thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2010-04-13 | — | — | US | disclosed |
| WO-2009073139-A2 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. (US) | 2009-06-11 | — | — | WO | disclosed |
| US-20090136517-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | OSI PHARMACEUTICALS, INC. | 2009-05-28 | — | — | US | disclosed |
| EP-1807419-B1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2009-05-27 | — | — | EP | disclosed |
| EP-1807419-B1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2009-05-27 | — | — | EP | disclosed |
| US-7524859-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524859-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| US-7524859-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2009-04-28 | — | — | US | disclosed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925676-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1925941-A1 | METHOD FOR PREDICTION OF THE EFFICACY OF VASCULARIZATION INHIBITOR | Eisai R&D Management Co., Ltd. (JP) | 2008-05-28 | — | — | EP | disclosed |
| EP-1590328-A4 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARM INC (US) | 2007-09-19 | — | — | EP | disclosed |
| EP-1807419-A1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2007-07-18 | — | — | EP | disclosed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | disclosed |
| EP-1797877-A1 | JOINT USE OF SULFONAMIDE BASED COMPOUND WITH ANGIOGENESIS INHIBITOR | Eisai Co., Ltd. (JP) | 2007-06-20 | — | — | EP | disclosed |
| US-20060247275-A1 | (2-carboxamido)(3-amino)thiophene compounds | CREW ANDREW P | 2006-11-02 | — | — | US | disclosed |
| US-7101893-B2 | (2-Carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. (US) | 2006-09-05 | — | — | US | disclosed |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | EISAI CO., LTD. (JP) | 2006-06-22 | — | — | US | disclosed |
| WO-2006047574-A1 | (2-CARBOXAMIDO)(3-AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2006-05-04 | — | — | WO | disclosed |
| EP-1590328-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI Pharmaceuticals, Inc. (US) | 2005-11-02 | — | — | EP | disclosed |
| US-6949563-B2 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2005-09-27 | — | — | US | disclosed |
| US-20050192320-A1 | (2-Carboxamido)(3-amino)thiophene compounds | CREW ANDREW P (US) | 2005-09-01 | — | — | US | disclosed |
| US-20050154014-A1 | (2-carboxamido)(3-amino) thiophene compounds | OSI PHARMACEUTICALS, INC. | 2005-07-14 | — | — | US | disclosed |
| US-20040186124-A1 | (2-carboxamido)(3-amino)thiophene compounds | OSI PHARMACEUTICALS, INC. | 2004-09-23 | — | — | US | disclosed |
| WO-2004063330-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
| WO-2004063330-A2 | (2-CARBOXAMIDO) (3-AMINO) THIOPHENE COMPOUNDS | OSI PHARMACEUTICALS, INC. (US) | 2004-07-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (22 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150374767-A1 | Treatment of Cancer | EGFR, ERBB2, MET | KDR 17/4885KIT 108/4885FLT1 37/4885 |
| US-20190083495-A1 | Methods Of Preventing Or Reducing A Fibrotic Response Using CSF1R Inhibitors | CSF1R, CSF3R, CD209 | KDR 1047/4885KIT 77/4885FLT1 163/4885 |
| US-20090136517-A1 | COMBINED TREATMENT WITH AN EGFR KINASE INHIBITOR AND AN INHIBITOR OF C-KIT | KIT, EGFR, AURKC | KDR 57/4885KIT 1/4885FLT1 97/4885 |
| US-11230589-B2 | Fusion molecules and uses thereof | RPS27A, CD2BP2, FGB | KDR 1552/4885KIT 1784/4885FLT1 1127/4885 |
| US-20040186124-A1 | (2-carboxamido)(3-amino)thiophene compounds | ABL1, NAT1, KRAS | KDR 869/4885KIT 1833/4885FLT1 666/4885 |
| US-20220169703-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | KDR 1464/4885KIT 1440/4885FLT1 984/4885 |
| US-11331313-B2 | KCC2 expression enhancing compounds and uses thereof | MECP2, SLC1A2, GRIN2C | KDR 2827/4885KIT 1644/4885FLT1 4472/4885 |
| US-20200085817-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | KDR 2827/4885KIT 1644/4885FLT1 4472/4885 |
| US-20060135486-A1 | Use of sulfonamide-including compounds in combination with angiogenesis inhibitors | FLT4, KDR, FLT1 | KDR 2/4885KIT 275/4885FLT1 3/4885 |
| US-20200237670-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | TP53, SCNN1B, HCCS | KDR 142/4885KIT 1203/4885FLT1 474/4885 |
| US-20050154014-A1 | (2-carboxamido)(3-amino) thiophene compounds | AADAC, PAM, TPMT | KDR 2418/4885KIT 4457/4885FLT1 2134/4885 |
| US-20230212679-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | KDR 4/4885KIT 157/4885FLT1 5/4885 |
| US-20140148483-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | KDR 4/4885KIT 157/4885FLT1 5/4885 |
| US-20130085152-A1 | Method For Assay On The Effect Of Vascularization Inhibitor | VEGFA, EDF1, HDGF | KDR 8/4885KIT 59/4885FLT1 6/4885 |
| US-20180021259-A1 | DYE-STABILIZED NANOPARTICLES AND METHODS OF THEIR MANUFACTURE AND THERAPEUTIC USE | TP53, HCCS, SCNN1B | KDR 167/4885KIT 1071/4885FLT1 241/4885 |
| US-20200199689-A1 | Method for Predicting Effectiveness of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | KDR 4/4885KIT 157/4885FLT1 5/4885 |
| US-20100092490-A1 | METHOD FOR ASSAY ON THE EFFECT OF VASCULARIZATION INHIBITOR | VEGFA, FLT4, MKI67 | KDR 6/4885KIT 59/4885FLT1 5/4885 |
| US-20220378782-A1 | KCC2 EXPRESSION ENHANCING COMPOUNDS AND USES THEREOF | MECP2, SLC1A2, GRIN2C | KDR 2827/4885KIT 1644/4885FLT1 4472/4885 |
| US-20060247275-A1 | (2-carboxamido)(3-amino)thiophene compounds | PCNA, MKI67, MYC | KDR 1639/4885KIT 325/4885FLT1 2142/4885 |
| US-20170191137-A1 | Method For Predicting Effectiveness Of Angiogenesis Inhibitor | VEGFA, BRAF, FLT4 | KDR 4/4885KIT 157/4885FLT1 5/4885 |
| US-20160009785-A1 | NOVEL FUSION MOLECULES AND USES THEREOF | RPS27A, CD2BP2, FGB | KDR 1464/4885KIT 1440/4885FLT1 984/4885 |
| US-20050192320-A1 | (2-Carboxamido)(3-amino)thiophene compounds | PCNA, MKI67, TPMT | KDR 1769/4885KIT 289/4885FLT1 2407/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.